Below Expected Outlook Pressured Boston Scientific (BSX) in Q1

Below Expected Outlook Pressured Boston Scientific (BSX) in Q1 Soumya Eswaran Wed, June 17, 2026 at 9:12 PM GMT+7 3 min read BSX ^GSPC Renaissance Investment Management, an investment management company, released its Q1 2026 “Large Cap Growth Strategy.” A copy of the letter can be downloaded here. Stocks fell sharply in the first quarter due to the Iran conflict. The Energy and Materials sectors outperformed, Financials and Consumer Discretionary lagged. Large-cap stocks underperformed smaller-cap stocks, and Value outperformed Growth. The portfolio outperformed the S&P 500’s -4.3% return but lagged the Russell 1000 Growth Index, which fell 9.8%. In this uncertain environment, the firm remains aware of the risks and emerging investment opportunities. In addition, you can check the Strategy’s top 5 holdings for its best picks for 2026.

In its first-quarter 2026 investor letter, Renaissance Investment Large Cap Growth Strategy highlighted Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is a medical technology company that manufactures and markets medical devices for use in various interventional medical specialties. On June 16, 2026, Boston Scientific Corporation (NYSE:BSX) closed at $46.92 per share. One-month return of Boston Scientific Corporation (NYSE:BSX) was -17.20%, and its shares lost 53.71% over the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a market capitalization of $69.74 billion.

Renaissance Investment Large Cap Growth Strategy stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2026 investor letter: